NCT02078661View on ClinicalTrials.gov

Safety and Efficacy of PG101 for Dry Eye Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Dry Eye Syndrome
Interventions
DRUG

PG101

A topical gel containing either 1% or 0.25% PG101 active.

Trial Locations (1)

01810

Andover Eye, Andover

All Listed Sponsors
collaborator

ORA, Inc.

INDUSTRY

lead

Rhodes Pharmaceuticals, L.P.

INDUSTRY

NCT02078661 - Safety and Efficacy of PG101 for Dry Eye Syndrome | Biotech Hunter | Biotech Hunter